Evidence syntheses — page 2
140 structured review questions, each with a registered PICO frame, a reproduced search, an included-studies table, a summary of findings and an amendment log.
Reviews
-
In adults with obesity and without type 2 diabetes, what is the effect of a glucagon-like peptide-1 receptor agonist compared with placebo on percentage change in body weight at the primary analysis timepoint?
High23 May 2025 -
In adults at elevated cardiovascular risk, what is the effect of a glucagon-like peptide-1 receptor agonist compared with placebo on major adverse cardiovascular events?
High24 Oct 2025 -
What can be concluded from a development programme that was discontinued, and how should the Institute record it?
Moderate09 Sep 2024 -
What is the effect of an amylin receptor agonist alone and in combination with a glucagon-like peptide-1 receptor agonist on body weight?
Moderate10 Aug 2026 -
What clinical evidence supports the uses under which growth-hormone secretagogues are supplied for research?
Very low26 May 2025 -
For neuropeptides holding a national marketing registration outside the jurisdictions the Institute routinely reviews, what evidence is retrievable and what can be concluded from it?
Very low13 May 2026 -
What is the evidence for thymic peptides in chronic viral hepatitis, sepsis and non-specific immune support?
Low17 Jun 2025 -
Does the cardiovascular effect of a glucagon-like peptide-1 receptor agonist established in secondary prevention extend to a primary-prevention population?
Moderate08 Apr 2026 -
In adults with metabolic dysfunction-associated steatohepatitis, do incretin receptor agonists improve histological outcomes, and does histological improvement predict clinical benefit?
Moderate12 Jan 2026 -
In adults with heart failure with preserved ejection fraction and obesity, what is the effect of an incretin receptor agonist on symptoms and on heart-failure events?
Moderate11 Oct 2024 -
In adults with obesity and moderate to severe obstructive sleep apnoea, what is the effect of a pharmacological weight-reducing agent on the apnoea–hypopnoea index?
Moderate25 Feb 2026 -
In adolescents with obesity, what is the effect of an incretin receptor agonist on body-mass index, and what is known about growth, bone accrual and pubertal outcomes?
Moderate09 Jan 2026 -
What is the relationship between the indications in which melanocortin receptor agonists have been evaluated and the uses under which they are supplied?
Low16 Oct 2024 -
What randomised evidence supports mitochondria-targeted peptides in primary mitochondrial disease and in age-related functional decline?
Low25 Jul 2025 -
What randomised human evidence exists for BPC-157 in any indication?
Very low03 Jul 2026 -
Does treatment with a glucagon-like peptide-1 receptor agonist increase residual gastric content at the time of elective procedural sedation?
Low13 Feb 2025 -
In the population defined for obesity and overweight in adults, is the effect of Tirzepatide maintained across the full duration of the contributing trials?
High15 Apr 2026 -
In the population defined for obesity and overweight in adults, what is the effect of Tirzepatide compared with the comparator used in its contributing trials on the anchor outcome for this indication?
High04 Aug 2025 -
In the population defined for obesity and overweight in adults, what is the incidence of adverse events leading to discontinuation with Tirzepatide compared with its comparator?
High26 Apr 2026 -
In the population defined for obesity and overweight in adults, is the effect of Semaglutide maintained across the full duration of the contributing trials?
High01 Aug 2025
page 2 of 7